RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...
Year Over Year First Quarter Revenues Increased 29% Double Digit Revenue Increases Year Over Year for Sixth Consecutive Quarter RICHLAND, WASHINGTON – November 8, 2018 — IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in...
Conference Call is November 8 at 4:30 p.m. ET/1:30 p.m. P RICHLAND, WASHINGTON – October 24, 2018 – IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today...
Year over year fourth quarter revenues increased 17% Sixth Consecutive Quarter of Year-Over-Year Revenue Increases Full year revenues increased 24% RICHLAND, Wash., September 25, 2018 — IsoRay (NYSE AMERICAN: ISR), a medical technology company and innovator in...
GammaTile Therapy is the Next Step in the Expansion of Cesium to Additional Markets RICHLAND, Wash., July 09, 2018 (GLOBE NEWSWIRE) — IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
RICHLAND, Wash., May 11, 2018 (GLOBE NEWSWIRE) — IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...
